Drug: Alecensa (Alectinib) to Treat NSCLC

Alecensa (Alectinib)Alecensa (Alectinib) – FDA Approved

Lung cancer is one of the leading causes of cancer deaths. Alecensa (alectinib) is an FDA approved drug for the treatment of non-small cell lung cancer (NSCLC). NSCLC is further divided into different types of cancers, depending upon the type of cells, different biologic and genetic differences within the cells and more.

Treatment of Lung Cancer

It is used to treat people with advanced ALK-positive NSCLC. The clinical trials of the drug have provided evidence of an effect on cancer. It works to block the activity of ALK protein which helps in preventing NSCLC cells from growing as well as spreading. FDA has granted Alecensa application breakthrough therapy designation.

In the clinical trials, Alecensa has worked to help in partial shrinkage of their lung tumors. It has a primary effect on tumors in the lung. It produces high anti-cancer responses among those patients having NSCLC who have stopped responding to Xalkori. These results have served as a basis for the FDA approval.

Dosage

The drug for treatment of lung cancer is taken by mouth and works to block the activity of ALK protein. The dosage depends on the severity, type and health conditions of the patient. It is available as a capsule and the contents of the capsule should not be opened or dissolved.

Side Effects

The common side effects of the drug include fatigue, constipation and muscle pain. It may cause serious side effects as well such as liver problems or slow heartbeats. If patients are exposed to sunlight, treatment with this drug may cause sunburn. You should always consult your doctor if you are having major side effects with intake of this drug.

Share your thoughts on the story in the comments.

 

The information offered in this blog is for educational purposes only. These details are not a substitute for medical advice. You should talk to your cancer specialist before making any changes in the lung cancer treatment.

Leave a Reply